Recently, it has been reported that small interfering RNA oligonucleotides or inhibitors directed against Nrf2 can enhance the sensitivity of pancreatic cancer cell lines to gemcitabine [13, 14]. Here, NFE2L2 is linked to pancreatic neoplasm.